Starrett will help identify, develop, and scale new businesses aimed at addressing persistent challenges across the cancer experience
NASHVILLE, Tenn., Sept. 29, 2026 — Thyme Companies, the family of businesses purpose-built to solve problems across the cancer care landscape, today announced that Carolyn Starrett has joined as executive vice president of new ventures, reporting to Executive Chairman Robin Shah. Her more than two decades of experience across oncology, clinical research, biopharma, and real-world data will shape Thyme Companies’ strategy as it expands beyond the existing Thyme Care platform.
“Carolyn has a rare ability to understand where the biggest problems exist across the cancer care journey and then build businesses that can solve them at scale,” said Shah. “This is our second stint working together, and I saw firsthand at Flatiron Health how she could take an idea, build an organization around it, and turn it into something that had real and lasting impact. She combines that strategic perspective with an incredible ability to execute. At Thyme Companies, we have an opportunity to think big about where the cancer care ecosystem needs to go and act quickly to build what’s missing. Carolyn is exactly the kind of leader I want alongside us as we meaningfully change cancer care.”
Before joining Thyme Companies, Starrett spent nearly a decade at Flatiron Health, a cancer data company that partners with hundreds of oncology practices and most of the industry’s leading cancer drug developers, which she joined in 2016 alongside Thyme’s founders. She served as Flatiron’s Chief Executive Officer from 2021 to 2025, during which time she led the expansion of its real-world evidence platform from roughly 400,000 to more than 5.5 million patient records, grew its OncoEMR platform to serve more than 4,500 oncology providers nationwide, and oversaw the company’s expansion into research sites across the United Kingdom, Germany and Japan. After stepping back from Flatiron, Starrett founded Starrett Advisory to work with companies at the intersection of healthcare, data and AI, and she currently serves as a board director for NeoGenomics.
“Cancer has always been personal to me. I spent the last decade focused on using data and technology to make cancer care better, but I’ve always wanted to get closer to the patient experience itself – what it takes to navigate our complex system and the ever changing universe of new treatment options,” said Starrett. “Joining Thyme Companies is a chance to build directly against that opportunity, informed by everything Thyme Care has already learned from the people living through it. And I get to do it with people I’ve wanted to work with again for years.”
Starrett’s appointment follows Thyme Companies’ recent launch and its Series E financing. Her arrival accelerates the work already underway as Thyme Companies pushes into new business lines.
About Thyme Companies
Thyme Companies is the parent of the Thyme family of businesses, focused on building companies against the disconnection in how cancer care is delivered, accessed and paid for. Anchored by Thyme Care, the nationally recognized oncology care company, Thyme Companies develops independent businesses connected by one mission: to transform the experience of cancer for the people living through it. To learn more, visit thymecompanies.com.
SOURCE Thyme Care
